

## **BIOTECH WEEK 2017**

### **Open Innovation Day (Preliminary Programme)**

*AESE Business School - Lisbon, 28 September 2017*

Portugal is associated with entrepreneurship and cutting-edge innovation. Health and Medical technologies are no exception. P-BIO over the years has played a role in this expansion, nurturing and collaborating with key players for the development of a successful ecosystem. This year, as part of the European Biotech week, P-BIO is partnering with key stakeholders to foster a multidisciplinary discussion on the potential and challenges faced by entrepreneurs and innovators during the development of their ventures.

The Portuguese biotech and life science ecosystem is living one of its most important and relevant years, with major mergers between Portuguese and foreign companies being closed, and the 2<sup>nd</sup> year of Web Summit organization in Lisbon. These examples are part of the incredible momentum we are living. The Open Innovation Day is part of this momentum and the inclusion of Pharma Business Developers, Business Angels, VCs and others stakeholders is a natural extension to allow a broad debate on the future of the Portuguese Biotech system.

This Open Innovation Day is part of the European Biotech Week Celebrations promoted by EuropaBio and was made possible with the crucial support of P-BIO and its member companies.

#### **PROGRAMME**

##### **LISBON, 28 September 2017 – Open Innovation Day**

**Local:** Lisboa, AESE – Business School, Calçada de Palma de Baixo 12

**9:30 Opening: Our Ecosystem** – Filipe Assoreira (P-BIO)

**9.40 Alternative Financing Systems for Innovative lifescience companies: Examples from the field**

**Moderator:** José Epifânio da Franca

Paulo Rodrigues da Silva (Euronext Lisbon) | Jan de Kerpel (Kempen) | Filipe Portela (Seedrs)

**10.15 New paradigms in Health: Medtech and eHealth**

**Moderators:** Seppo Makinen (Venture Capitalist), João Martins (Pathena), Francisco Ferreira Pinto (BusyAngels)

Selected company presentations (6-8 companies) and Q&A with Audience (Business Developers)

Companies dedicated to new technologies for Health, including monitoring technologies and other eHealth and medtech approaches. Companies ranging from pre-revenue to commercial stage.

*Lunch*

**14.30 From prevention to diagnosis and treatment**

**Moderators:** David Cristina (Portugal Ventures), Sérgio Simões (Bluepharma)

Selected company presentations (6-8 companies) and Q&A with Audience (Business Developers)

Companies with platform technologies focused on therapeutics, diagnostics and vaccines. Companies ranging from pre-revenue to commercial stage.

16.30 Coffee-break & Parallel meetings (one-to-one discussions)

17.15 Biotech Week take-home messages – Filipe Assoreira (P-BIO)

**17.30 Keynote – The European perspective – Hans GCP Schikan, PharmD | Former CEO Prosenza**

**18h00 – 19h00 Debate Session: “Working together to make our ecosystem evolve”**

**Moderator:** José Ramalho Fontes (AESE)

João Almeida Lopes (Apifarma) | Nuno Arantes-Oliveira (P-BIO)

Carlos Faro | Healthcluster Portugal (TBC) | António Murta (Pathena)

19h00 – Wrap-up

#### **Organization:**

P-BIO - Portugal's Biotechnology Industry Organization

Contacts mail: [smonteiro@p-bio.org](mailto:smonteiro@p-bio.org) | phone: +351 231410960 | [www.pbio.pt](http://www.pbio.pt)

Sponsor:



Partner:



## Companies Presenting

**Coimbra Genomics** | <http://www.coimbra-genomics.com>

*Coimbra Genomics, S.A. has developed and is commercializing ELSIE, a first-in-class digital platform that allows physicians of any speciality to use information on their patient's genome during a regular medical appointment. By combining the capacity to provide fast, accurate, on-the-spot answers based on each patient's genome with an efficient articulation with multiple providers of specific genetic tests, ELSIE is the first simple, highly scalable and completely secure way to perform personalized medicine.*

**Serfarma** | <https://www.serfarma.pt/en/>

*We optimize innovative methodologies to support both the patient and healthcare professionals, aiming at the continuous improvement of the medicines use process and of health outcomes.*

**Tonic app** | <http://www.tonicapp.com>

*Communication is one of the most underestimated problems in healthcare. Tonic App is a B2C / B2B mobile platform for dedicated and safe medical communication and content. Learn more at [www.tonicapp.com](http://www.tonicapp.com).*

**Nuada** | <http://nuada.pt>

*Nuada is a revolutionary hand function improving system, safe, light and small that was designed to be affordable and non-intrusive.*

**Intellicare (TBC)** | <http://www.intellicare.pt/pt/>

**Sensifuture (TBC)** | <http://www.sensingfuture.pt/index.php/en>

**Plux (TBC)** | <http://www.plux.info/index.php/en/>

**Immunethep** | <http://www.immunethep.com>

*Develops anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections*

**Stemmatters** | <http://www.stemmatters.com>

*Stemmatters is a regenerative medicine company focussing in developing breakthrough technologies for cell delivery and retention. Our technology is based on an innovative platform with potential application in multiple clinical domains.*

**Criam** | <http://www.criamtech.com>

*Portable medical device which identifies human blood type and sub-type in 3 minutes and detects diseases.*

**FASTinov** | <http://www.fastinov.com>

*Rapid antimicrobial susceptibility testing are an urgent need in order to quickly treat patients with target therapy avoiding the increasing of resistance. A new phenotypical method is now available, using flow cytometry technology to determine the susceptibility profile directly from positive blood cultures, providing results in 2 hours (versus minimum 48 hours of routine tests). Additionally the mechanism of resistance could be provided.*

**Leaserleap** | <http://www.laserleap.com>

*LaserLeap is a 40 country-patented technology to deliver medicines and cosmetics through the skin. It is based on the generation of high-frequency ultrasound using a portable laser and a small device (piezophotonic materials) that efficiently converts light pulses into pressure waves. The pressure waves are painless but capable of changing the skin structure for a couple of minutes, enough time to facilitate the transport of medicines and cosmetics through the skin, leaving no footprint. The process is safe and skin recovers its protective function in few minutes.*

**Luzitin** | <http://www.luzitin.pt>

*Luzitin SA is a portuguese pharmaceutical development company focused on the pursuit of innovative solutions for photodynamic therapy (PDT). Luzitin's technology consists in a combination of a proprietary new generation photosensitizer (Redaporfin) with a specific infrared-laser medical device able to selectively destroy solid tumours. Redaporfin PDT demonstrated in a Phase I/IIa POC clinical trial to have a marked antitumor effect, a very favourable safety profile and the treatment was well tolerated by the patients.*

**Business Developers Invited:**

**Alexion**

**Amgen**

**J&J**

**Celgene**

**CSLBerrhing**

**Merck**

**Pfizer**

**Sanofi**

**Shire**

**Sobi**